ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OBD Oxford Biodynamics Plc

9.40
-0.09 (-0.95%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.09 -0.95% 9.40 9.32 9.48 9.50 9.32 9.50 708,095 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.34M -10.83M -0.0535 -1.74 18.85M

Oxford BioDynamics PLC Notice of Results (0248A)

27/05/2021 9:00am

UK Regulatory


Oxford Biodynamics (LSE:OBD)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Oxford Biodynamics Charts.

TIDMOBD

RNS Number : 0248A

Oxford BioDynamics PLC

27 May 2021

27 May 2021

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

Notice of Interim Results

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch(R) 3D genomics platform, expects to announce its interim results for the half-year ended 31 March 2021 on 15 June 2021.

-Ends-

For further details please contact:

 
 Oxford BioDynamics Plc                                     Tel: +44 (0)1865 
  Jon Burrows, CEO                                                    518910 
  Paul Stockdale, CFO 
 Shore Capital - Nominated Adviser and                        Tel: +44 (0)20 
  Broker                                                           7408 4090 
  Advisory: Edward Mansfield / John More 
  Broking: Fiona Conroy 
 Instinctif Partners                                          Tel: +44 (0)20 
  Melanie Toyne-Sewell / Agnes Stephens                            7457 2020 
  /                                         OxfordBioDynamics@instinctif.com 
  Katie Duffell / Nathan Billis 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit . Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia

For more information, please visit the Company's website , www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .

About EpiSwitch(R)

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

Oxford BioDynamics is leveraging its technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, neurodegenerative and autoimmune diseases, to follow its commercial EpiSwitch (R) CST (Covid Severity Test).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDDLBLFELEBBX

(END) Dow Jones Newswires

May 27, 2021 04:00 ET (08:00 GMT)

1 Year Oxford Biodynamics Chart

1 Year Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

Your Recent History

Delayed Upgrade Clock